A citation-based method for searching scientific literature


List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Definition of minimal disease activity in psoriasis.
G Carretero, J M Carrascosa, L Puig, J L Sánchez-Carazo, A López-Ferrer, P Cueva, C Soria, R Rivera, I Belinchón. J Eur Acad Dermatol Venereol 2021
8
50



Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
Elena Del Alcázar, Anna López-Ferrer, Álvaro Martínez-Doménech, Ricardo Ruiz-Villaverde, Mª Del Mar Llamas-Velasco, Vicenç Rocamora, Marc Julià, Jaime Notario, Lourdes Rodríguez Fernández-Freire, Antonio Sahuquillo-Torralba,[...]. Dermatol Ther 2022
7
50


Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice.
Miriam Almirall, Jesús Rodriguez, Lourdes Mateo, José Manuel Carrascosa, Jaime Notario, Fernando Gallardo. Clin Rheumatol 2017
13
50

Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.
Philip J Mease, Iain B McInnes, Lai-Shan Tam, Kiefer Eaton, Steve Peterson, Agata Schubert, Soumya D Chakravarty, Anna Parackal, Chetan S Karyekar, Sandhya Nair,[...]. Rheumatology (Oxford) 2021
19
50

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
C Antoni, G G Krueger, K de Vlam, C Birbara, A Beutler, C Guzzo, B Zhou, L T Dooley, A Kavanaugh. Ann Rheum Dis 2005
523
50

A case of erythrodermic psoriasis successfully treated with guselkumab.
Matteo Megna, Angelo Ruggiero, Elisa Camela, Gabriella Fabbrocini, Claudio Marasca. Dermatol Ther 2020
20
50

Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases.
George E Fragoulis, Stefan Siebert, Iain B McInnes. Annu Rev Med 2016
112
50

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
Philip J Mease, Dafna D Gladman, Christopher T Ritchlin, Eric M Ruderman, Serge D Steinfeld, Ernest H S Choy, John T Sharp, Peter A Ory, Renee J Perdok, Mark A Weinberg. Arthritis Rheum 2005
685
50

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
Philip J Mease, Proton Rahman, Alice B Gottlieb, Alexa P Kollmeier, Elizabeth C Hsia, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Yanli Zhuang,[...]. Lancet 2020
106
50

Real-life experience of guselkumab in patients with psoriasis.
Igor Snast, Shany Sherman, Roie Holzman, Emmilia Hodak, Lev Pavlovsky. Dermatol Ther 2020
16
50

Real-life efficacy of guselkumab in patients with early psoriatic arthritis.
Ilenia Pantano, Daniele Mauro, Francesca Romano, Alessio Gambardella, Mario Valenti, Davide Simone, Daniela Iacono, Antonio Costanzo, Giuseppe Argenziano, Francesco Ciccia. Rheumatology (Oxford) 2022
6
50

Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
A Ruggiero, G Fabbrocini, E Cinelli, S S Ocampo Garza, E Camela, M Megna. Clin Exp Dermatol 2022
28
50

Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group.
Elena Del Alcázar, Anna López-Ferrer, Álvaro Martínez-Doménech, Marc Julià, Ricardo Ruiz-Villaverde, Lourdes Rodríguez Fernández-Freire, Jaime Notario, Mar Llamas-Velasco, Marta Ferran, José Manuel Carrascosa. J Dermatolog Treat 2022
1
100

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.
Philip J Mease, Alan J Kivitz, Francis X Burch, Evan L Siegel, Stanley B Cohen, Peter Ory, David Salonen, Joel Rubenstein, John T Sharp, Wayne Tsuji. Arthritis Rheum 2004
689
50

Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.
Iain B McInnes, Proton Rahman, Alice B Gottlieb, Elizabeth C Hsia, Alexa P Kollmeier, Xie L Xu, Yusang Jiang, Shihong Sheng, May Shawi, Soumya D Chakravarty,[...]. Arthritis Rheumatol 2022
9
50

Psoriatic arthritis: epidemiology, clinical features, course, and outcome.
D D Gladman, C Antoni, P Mease, D O Clegg, P Nash. Ann Rheum Dis 2005
905
50

Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis.
Ricardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire, Jose Carlos Armario-Hita, Amalia Pérez-Gil, Fiorella Vasquez Chinchay, Manuel Galán-Gutiérrez. Dermatol Ther 2022
2
50

Switch from ustekinumab to guselkumab in patients with psoriasis in real clinical practice using the "minimal disease activity" parameter.
Jorge Magdaleno-Tapial, Sergio Santos-Alarcón, Marta Carolina Serra-Torres, Luca Schneller-Pavelescu, Cristina López-Martí, José María Ortiz-Salvador, Pablo Hernández-Bel, José Luis Sánchez-Carazo, Amparo Pérez-Ferriols. Dermatol Ther 2022
2
50

The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people.
Fausto Salaffi, Marina Carotti, Stefania Gasparini, Michele Intorcia, Walter Grassi. Health Qual Life Outcomes 2009
219
50

The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis.
George E Fragoulis, Stefan Siebert. Musculoskeletal Care 2022
1
100

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Atul Deodhar, Philip S Helliwell, Wolf-Henning Boehncke, Alexa P Kollmeier, Elizabeth C Hsia, Ramanand A Subramanian, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou,[...]. Lancet 2020
108
50

Real-life effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study.
F Benhadou, P D Ghislain, F Guiot, F Willaert, V Del Marmol, J Lambert, R Soenen, H Fierens, M de la Brassinne. J Eur Acad Dermatol Venereol 2020
18
50

Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial.
Sascha Gerdes, Beate Bräu, Matthias Hoffmann, Bernhard Korge, Dariusch Mortazawi, Franca Wiemers, Sven Wegner, Yvonne Personke, Mario Gomez, Michael Sticherling. J Dermatol 2021
6
50

Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period.
Matteo Megna, Eleonora Cinelli, Lucia Gallo, Elisa Camela, Angelo Ruggiero, Gabriella Fabbrocini. Arch Dermatol Res 2022
21
50

Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study.
Matteo Megna, Luca Potestio, Gabriella Fabbrocini, Angelo Ruggiero. Psoriasis (Auckl) 2022
1
100

Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life study.
Matteo Megna, Luca Potestio, Angelo Ruggiero, Elisa Camela, Gabriella Fabbrocini. Dermatol Ther 2022
8
50

Treatment recommendations for psoriatic arthritis.
C T Ritchlin, A Kavanaugh, D D Gladman, P J Mease, P Helliwell, W-H Boehncke, K de Vlam, D Fiorentino, O Fitzgerald, A B Gottlieb,[...]. Ann Rheum Dis 2009
380
50

Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study.
Angelo Ruggiero, Gabriella Fabbrocini, Eleonora Cinelli, Matteo Megna. Dermatol Ther 2022
11
50

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Iain B McInnes, Philip J Mease, Bruce Kirkham, Arthur Kavanaugh, Christopher T Ritchlin, Proton Rahman, Désirée van der Heijde, Robert Landewé, Philip G Conaghan, Alice B Gottlieb,[...]. Lancet 2015
530
50

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Philip J Mease, Désirée van der Heijde, Christopher T Ritchlin, Masato Okada, Raquel S Cuchacovich, Catherine L Shuler, Chen-Yen Lin, Daniel K Braun, Chin H Lee, Dafna D Gladman. Ann Rheum Dis 2017
313
50

Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study.
Matteo Megna, Luca Potestio, Angelo Ruggiero, Elisa Camela, Gabriella Fabbrocini. J Dermatolog Treat 2022
13
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.